Project Grant K38CA282963
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$104K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
This $101,948 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize germline variants and perform functional validation of variants in a zebrafish model of high-risk pediatric acute myeloid leukemia (AML). The ultimate goal is to determine if predisposition risk factors like germline mutations and viral infections can be mitigated through screening or prophylaxis. The award, effective September 1,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $342,102 to The Johns Hopkins University to conduct research on the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The research aims to elucidate the mechanisms by which HMGA1 drives leukemogenesis and therapy resistance in this aggressive form of AML, which is resistant to current treatments. The project will involve defining the role of...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,834 to Duke University to investigate how inhibiting the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) cells to metabolic dysregulation, leading to cell death. The research aims to determine how ABL kinases mediate metabolic function, the mechanism of metabolic dysregulation following ABL inhibition, and the extent to which combining ABL kinase...